315 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Kelly
    Kelly
  4. Gerecitano
    Gerecitano
  5. O'Reilly
    O'Reilly
  6. Slovin
    Slovin
  7. Smart-Curley
    Smart-Curley
  8. Morris
    Morris
  9. Schwartz
    Schwartz
  10. Zelenetz
    Zelenetz

Groups

  1. Department of Medicine (223)
  2. Solid Tumor Oncology Division (164)
  3. Hematologic Malignancies, Division of (77)
  4. Genitourinary Oncology Service (67)
  5. Center for Hematologic Malignancies (53)
  6. Epidemiology and Biostatistics (47)
  7. Biostatistics Service (45)
  8. Survivorship Research (45)
  9. Radiology, Department of (42)
  10. Nursing (41)
  1. "hyperglycemia"
Formats
  1. Journal Article (294)
  2. Review (17)
  3. Guidelines (2)
  4. Correspondence (1)
  5. Research Letter (1)
Groups
  1. Department of Medicine (223)
  2. Solid Tumor Oncology Division (164)
  3. Hematologic Malignancies, Division of (77)
  4. Genitourinary Oncology Service (67)
  5. Center for Hematologic Malignancies (53)
  6. Epidemiology and Biostatistics (47)

More Groups

People
  1. Robert Motzer (28)
  2. Howard Scher (15)
  3. William Kelly (14)
  4. Eileen O'Reilly (11)
  5. John Gerecitano (11)
  6. Susan Slovin (11)

More People

Years
  1. 2025 (8)
  2. 2024 (20)
  3. 2023 (20)
  4. 2022 (15)
  5. 2021 (9)
  6. 2020 (22)

More Years

Publications
  1. Journal of Clinical Oncology (27)
  2. Clinical Cancer Research (20)
  3. Cancer (14)
  4. Lancet Oncology (14)
  5. Annals of Oncology (12)
  6. Investigational New Drugs (12)

More Publications

Publishers
  1. Elsevier Inc. (42)
  2. Springer (32)
  3. American Society of Clinical Oncology (28)
  4. Elsevier Science, Inc. (23)
  5. Oxford University Press (23)
  6. American Association for Cancer Research (21)

More Publishers

Results (315)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: A retrospective, multi-center review
    Journal Article

    Flank, J.; Thackray, J.; Nielson, D.; August, A.; Schechter, T.; Alexander, S.; Sung, L.; Dupuis, L. L.
    Pediatric Blood and Cancer (2015)

    Fulltext@MSK | Save
  • Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: Preclinical characterization and phase I clinical trial
    Journal Article

    Di Cosimo, S.; Sathyanarayanan, S.; Bendell, J. C.; Cervantes, A.; Stein, M. N.; Braña, I.; Roda, D.; Haines, B. B.; Zhang, T.; Winter, C. G.; more...
    Clinical Cancer Research (2015)

    Fulltext@MSK | Save
  • Synergistic exacerbation of mitochondrial and synaptic dysfunction and resultant learning and memory deficit in a mouse model of diabetic Alzheimer's disease
    Journal Article

    Wang, Y.; Wu, L.; Li, J.; Fang, D.; Zhong, C.; Chen, J. X.; Yan, S. S.
    Journal of Alzheimer's Disease (2015)

    Fulltext@MSK | Save
  • Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
    Journal Article

    Kaley, T. J.; Wen, P.; Schiff, D.; Ligon, K.; Haidar, S.; Karimi, S.; Lassman, A. B.; Nolan, C. P.; De Angelis, L. M.; Gavrilovic, I.; more...
    Neuro-Oncology (2014)

    Fulltext@MSK | Save
  • Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors
    Journal Article

    Yu, H. A.; Riely, G. J.; Lovly, C. M.
    Clinical Cancer Research (2014)

    Fulltext@MSK | Save
  • A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression
    Journal Article

    Li, D.; Pant, S.; Ryan, D. P.; Laheru, D.; Bahary, N.; Dragovich, T.; Hosein, P. J.; Rolfe, L.; Saif, M. W.; Lavalle, J.; more...
    Pancreatology (2014)

    Fulltext@MSK | Save
  • Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study
    Journal Article

    Gadgeel, S. M.; Gandhi, L.; Riely, G. J.; Chiappori, A. A.; West, H. L.; Azada, M. C.; Morcos, P. N.; Lee, R. M.; Garcia, L.; Yu, L.; more...
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma
    Journal Article

    Motzer, R. J.; Barrios, C. H.; Kim, T. M.; Falcon, S.; Cosgriff, T.; Harker, W. G.; Srimuninnimit, V.; Pittman, K.; Sabbatini, R.; Rha, S. Y.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: A non-randomised, phase 1b study
    Journal Article

    Younes, A.; Thieblemont, C.; Morschhauser, F.; Flinn, I.; Friedberg, J. W.; Amorim, S.; Hivert, B.; Westin, J.; Vermeulen, J.; Bandyopadhyay, N.; more...
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study
    Journal Article

    Pappo, A. S.; Vassal, G.; Crowley, J. J.; Bolejack, V.; Hogendoorn, P. C. W.; Chugh, R.; Ladanyi, M.; Grippo, J. F.; Dall, G.; Staddon, A. P.; more...
    Cancer (2014)

    Fulltext@MSK | Save